经肝动脉化疗栓塞联合免疫靶向治疗晚期 不可切除肝内胆管细胞癌的临床疗效

Clinical efficacy of transarterial chemoembolization combined with immunotherapy plus target therapy for advanced unresectable intrahepatic cholangiocarcinoma

  • 摘要: 晚期肝内胆管细胞癌是仅次于肝细胞肝癌的常见肝脏恶性肿瘤,其发病隐匿,治疗手段 有限,预后较差。晚期不可切除肝内胆管细胞癌的推荐治疗方案为系统性治疗。笔者报道 1例肝内 胆管细胞癌病人行肝动脉化疗栓塞联合免疫靶向治疗的临床经验,其研究结果显示:病人疾病无进展 生存时间可达15个月,效果良好。

     

    Abstract: Advanced intrahepatic cholangiocarcinoma(ICC) is one of the most common hepatic malignant tumors besides hepatocellular carcinoma, with occult onset, limited treatment and poor prognosis. Systemic treatment is a recommendable solution for advanced unresectable ICC. The authors reported the clinical experience of an ICC patient who underwent transarterial chemoembolization combined with immunotherapy plus target therapy

     

/

返回文章
返回